PDCD1 and neoplasm: Likewise, combined immunotherapy with anti-CXCR4 and anti-PD-1 antibodies conferred a noteworthy survival advantage compared to monotherapy treatment, also modulating tumor-infiltrating leukocytes in the glioblastoma microenvironment as evaluated by an in vivo model [136].